Adverts

Open Access Articles- Top Results for Cevimeline

Cevimeline

</th></tr></th></tr>
Cevimeline
File:Cevimeline.svg
File:Cevimeline 3D.png
Systematic (IUPAC) name
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
Clinical data
Trade names Evoxac
AHFS/Drugs.com monograph
MedlinePlus a608025
  • C
  • (Prescription only)
Oral
Pharmacokinetic data
Protein binding < 20%
Identifiers
107233-08-9 7pxY
N07AX03
PubChem CID 83898
DrugBank DB00185 7pxY
ChemSpider 75707 7pxY
UNII K9V0CDQ56E 7pxY
KEGG D07667 7pxY
ChEBI CHEBI:3568 7pxN
ChEMBL CHEMBL1201267 7pxN
Chemical data
Formula C10H17NOS
199.31308 g/mol
 14pxN (what is this?)  (verify)

Cevimeline (Evoxac) is a parasympathomimetic and muscarinic agonist,[1] with particular effect on M1 and M3 receptors. It is used in the treatment of dry mouth associated with Sjögren's syndrome.

Mechanism of action

By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.

Side effects

Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping.[2]

Contraindications include asthma and angle closure glaucoma.[citation needed]

See also

References

  1. ^ Ono M, Takamura E, Shinozaki K et al. (July 2004). "Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study". Am. J. Ophthalmol. 138 (1): 6–17. PMID 15234277. doi:10.1016/j.ajo.2004.02.010. 
  2. ^ [1] MedicineNet: Cevimeline. Accessed 10/12/2007

External links

Template:Navbox with collapsible sections